Defining the biology component of the drug discovery strategy for malaria eradication

摘要: Malaria is still considered a deadly scourge in Africa, Asia, and South America despite improved vector control curative treatments with new antimalarial combinations. The next challenge to work towards disease eradication. To achieve this goal it crucial develop, validate, integrate biological assays into test cascades that align the key target product profiles. For anti-relapse, parent molecule should kill hypnozoites or cause activation of Plasmodium vivax liver stages. transmission blocking, dual equal-activity antimalarials killing both asexual sexual parasite stages human blood are favored. Finally, by assessing cross resistance generating drug laboratory, expected medicines acceptable profiles will be forthcoming.